Phase 2 Clinical Trial to Study Survivin Peptide Vaccine for Lung Cancer Prevention

National Cancer Institute (NCI) has announced an interventional clinical trial to assess the feasibility of a survivin peptide vaccine, called SurVaxM, as an interception agent in patients at high risk for lung cancer. The trial's principal investigator is Saikrishna S Yendamuri, and it aims to enroll 80 participants from the USA. The trial will evaluate whether the SurVaxM vaccine can activate the immune system to prevent lung cancer in high-risk patients.

Key Takeaways:

• The Phase 2 clinical trial is designed to test the efficacy of the SurVaxM vaccine in preventing lung cancer in high-risk patients.
• The trial will involve 80 participants from the USA, who will receive the SurVaxM vaccine with montanide and sargramostim.
• The vaccine is expected to activate the immune system to produce an immune cell response against cancer cells that express survivin, leading to decreased tumor cell proliferation and tumor cell death.
• The trial is an interventional study, meaning that the treatment will be administered to the participants.
• The primary objective of the study is to assess the feasibility of the SurVaxM vaccine as an interception agent in patients at high risk for lung cancer.
• Saikrishna S Yendamuri is the principal investigator of the trial, and the study is being conducted by the National Cancer Institute.

Statistics:

• 80 participants from the USA will be enrolled in the trial.
• The trial will be conducted in multiple centers, with the principal investigator being Saikrishna S Yendamuri.

Sources:

• ClinicalTrials.gov - Study ID: NCT07169617
• National Cancer Institute (NCI) - Interventional Clinical Trial for Lung Cancer Prevention